Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.73 |
| ▸ | SRC | P12931 | 5/20 | 0.54 |
| ▸ | KDR | P35968 | 2/20 | 0.54 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.54 |
| ▸ | GAK | O14976 | 1/20 | 0.54 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.54 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.54 |
| ▸ | STK10 | O94804 | 1/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | FYN | P06241 | 1/20 | 0.54 |
| ▸ | YES1 | P07947 | 1/20 | 0.54 |
| ▸ | LYN | P07948 | 1/20 | 0.54 |
| ▸ | RET | P07949 | 1/20 | 0.54 |
| ▸ | HCK | P08631 | 1/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.54 |
| ▸ | FGR | P09769 | 1/20 | 0.54 |
| ▸ | KIT | P10721 | 1/20 | 0.54 |
| ▸ | BCR | P11274 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4036496 | 0.94 | EGFR (0.82) | EGFRSRCKDRBMPR1BGAK | |
| SCHEMBL4040545 | 0.93 | EGFR (0.81) | EGFRSRCKDRBMPR1BGAK | |
| SCHEMBL4202522 | 0.92 | EGFR (0.78) | EGFRSRCKDRBMPR1BGAK | |
| SCHEMBL4037439 | 0.92 | EGFR (0.78) | EGFRSRCKDRBMPR1BGAK | |
| SCHEMBL4037343 | 0.91 | EGFR (0.76) | EGFRSRCKDRLCKYES1 | |
| SCHEMBL4037338 | 0.91 | EGFR (0.78) | EGFRSRCKDRBMPR1BGAK | |
| SCHEMBL4031547 | 0.91 | EGFR (0.77) | EGFRSRCKDRBMPR1BGAK | |
| SCHEMBL4036828 | 0.91 | EGFR (0.77) | EGFRSRCKDRBMPR1BGAK | |
| SCHEMBL4034522 | 0.91 | EGFR (0.74) | EGFRSRCKDRBMPR1BGAK | |
| SCHEMBL4037393 | 0.91 | EGFR (0.84) | EGFRSRCKDRBMPR1BGAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444211-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | claimed |
| WO-2003040109-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | claimed |
| EP-1444211-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-01-21 | — | — | EP | disclosed |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-19 | — | — | US | disclosed |
| EP-1444211-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040109-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | EGFR 2/4885SRC 39/4885KDR 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.